{"pmid":32303509,"title":"Harnessing CAR T Cell Insights to Develop Treatments for Hyperinflammatory Responses in COVID-19 patients.","text":["Harnessing CAR T Cell Insights to Develop Treatments for Hyperinflammatory Responses in COVID-19 patients.","Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with of COVID-19.","Cancer Discov","Agarwal, Sangya","June, Carl H","32303509"],"abstract":["Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with of COVID-19."],"journal":"Cancer Discov","authors":["Agarwal, Sangya","June, Carl H"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303509","week":"202016|Apr 13 - Apr 19","doi":"10.1158/2159-8290.CD-20-0473","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664431720418508801,"score":8.233237,"similar":[{"pmid":32267560,"title":"Considerations for statin therapy in patients with COVID-19.","text":["Considerations for statin therapy in patients with COVID-19.","Current coronavirus pandemic named coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.(1) Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID-19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-alpha) and chemokines.(2-3) So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.(3-4).","Pharmacotherapy","Dashti-Khavidaki, Simin","Khalili, Hossein","32267560"],"abstract":["Current coronavirus pandemic named coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the third coronavirus outbreak during the current century after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses.(1) Acute respiratory distress syndrome (ARDS) is an immunopathologic event and main cause of death following COVID-19. The main mechanism of ARDS is uncontrolled systemic inflammatory response and cytokine storm following release of proinflammatory cytokines (such as interferons (IFN), interleukines (IL), tumor necrosis factor (TNF)-alpha) and chemokines.(2-3) So, some Chinese researchers proposed or used anti-inflammatory agents in the treatment regimen of patients with COVID-19.(3-4)."],"journal":"Pharmacotherapy","authors":["Dashti-Khavidaki, Simin","Khalili, Hossein"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267560","week":"202015|Apr 06 - Apr 12","doi":"10.1002/phar.2397","keywords":["COVID-19","Coronavirus infection","HMG-CoA reductase inhibitor","SARS-CoV","Statin"],"source":"PubMed","locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663609715717832705,"score":112.648026},{"pmid":32298807,"title":"CAR T Cell Therapy During the COVID-19 Pandemic.","text":["CAR T Cell Therapy During the COVID-19 Pandemic.","The COVID-19 pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically we address: 1) necessary resources for safe administration of cell therapies; 2) determinants of cell therapy utilization; 3) selection among patients with B-cell non-Hodgkin lymphomas and 4) B-cell acute lymphocytic leukemia; 5) supportive measures during cell therapy administration; 6) use and prioritization of tocilizumab, and 7) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resources allocation is of the utmost importance and the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Though these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy.","Biol Blood Marrow Transplant","Bachanova, Veronika","Bishop, Michael R","Dahi, Parastoo","Dholaria, Bhagirathbhai","Grupp, Stephan A","Hayes-Lattin, Brandon","Janakiram, Murali","Maziarz, Richard T","McGuirk, Joseph P","Nastoupil, Loretta J","Oluwole, Olalekan O","Perales, Miguel-Angel","Porter, David L","Riedell, Peter A","32298807"],"abstract":["The COVID-19 pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically we address: 1) necessary resources for safe administration of cell therapies; 2) determinants of cell therapy utilization; 3) selection among patients with B-cell non-Hodgkin lymphomas and 4) B-cell acute lymphocytic leukemia; 5) supportive measures during cell therapy administration; 6) use and prioritization of tocilizumab, and 7) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resources allocation is of the utmost importance and the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Though these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy."],"journal":"Biol Blood Marrow Transplant","authors":["Bachanova, Veronika","Bishop, Michael R","Dahi, Parastoo","Dholaria, Bhagirathbhai","Grupp, Stephan A","Hayes-Lattin, Brandon","Janakiram, Murali","Maziarz, Richard T","McGuirk, Joseph P","Nastoupil, Loretta J","Oluwole, Olalekan O","Perales, Miguel-Angel","Porter, David L","Riedell, Peter A"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298807","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.bbmt.2020.04.008","keywords":["COVID-19","Cellular therapy","Chimeric antigen receptor T-cells","Coronavirus","Pandemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["non-Hodgkin"],"_version_":1664266651306033152,"score":111.119415},{"pmid":32259129,"title":"Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen.","text":["Metronidazole; a Potential Novel Addition to the COVID-19 Treatment Regimen.","Coronavirus disease 2019 or COVID-19 has rapidly emerged as a global pandemic. This viral infection involves the upper respiratory tract and could lead to severe pneumonia with respiratory distress or even death. Certain studies have found higher initial plasma levels of most pro-inflammatory cytokines during the course of the infection. In this context, both in vitro and in vivo studies have revealed that metronidazole could decrease the levels of several cytokines, which are known to increase during the COVID-19 infection, including interleukin (IL)8, IL6, IL1B, tumor necrosis factor (TNF)alpha, IL12, IL1alpha, and interferon (IFN)gamma, as well as the levels of C-reactive protein (CRP) and neutrophil count. Furthermore, the drug could decrease neutrophil-generated reactive oxygen species during inflammation. Metronidazole could counteract majority of the immunopathological manifestations of the COVID-19 infection. Therefore, studies with a large sample size are required to determine the efficacy of metronidazole in the treatment of COVID-19 infection.","Arch Acad Emerg Med","Gharebaghi, Reza","Heidary, Fatemeh","Moradi, Mohammad","Parvizi, Maryam","32259129"],"abstract":["Coronavirus disease 2019 or COVID-19 has rapidly emerged as a global pandemic. This viral infection involves the upper respiratory tract and could lead to severe pneumonia with respiratory distress or even death. Certain studies have found higher initial plasma levels of most pro-inflammatory cytokines during the course of the infection. In this context, both in vitro and in vivo studies have revealed that metronidazole could decrease the levels of several cytokines, which are known to increase during the COVID-19 infection, including interleukin (IL)8, IL6, IL1B, tumor necrosis factor (TNF)alpha, IL12, IL1alpha, and interferon (IFN)gamma, as well as the levels of C-reactive protein (CRP) and neutrophil count. Furthermore, the drug could decrease neutrophil-generated reactive oxygen species during inflammation. Metronidazole could counteract majority of the immunopathological manifestations of the COVID-19 infection. Therefore, studies with a large sample size are required to determine the efficacy of metronidazole in the treatment of COVID-19 infection."],"journal":"Arch Acad Emerg Med","authors":["Gharebaghi, Reza","Heidary, Fatemeh","Moradi, Mohammad","Parvizi, Maryam"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259129","week":"202015|Apr 06 - Apr 12","keywords":["COVID-19","Coronavirus disease","Cytokines","Interleukins","Metronidazole"],"source":"PubMed","locations":["IL1alpha","IL12"],"topics":["Treatment"],"weight":1,"_version_":1663450393532694529,"score":93.61496},{"pmid":32228226,"title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.","text":["Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.","Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health. However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease. To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients. Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the association between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B. Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia. The transcriptome dataset of COVID-19 patients would be a valuable resource for clinical guidance on anti-inflammatory medication and understanding the molecular mechansims of host response.","Emerg Microbes Infect","Xiong, Yong","Liu, Yuan","Cao, Liu","Wang, Dehe","Guo, Ming","Jiang, Ao","Guo, Dong","Hu, Wenjia","Yang, Jiayi","Tang, Zhidong","Wu, Honglong","Lin, Yongquan","Zhang, Meiyuan","Zhang, Qi","Shi, Mang","Liu, Yingle","Zhou, Yu","Lan, Ke","Chen, Yu","32228226"],"abstract":["Circulating in China and 158 other countries and areas, the ongoing COVID-19 outbreak has caused devastating mortality and posed a great threat to public health. However, efforts to identify effectively supportive therapeutic drugs and treatments has been hampered by our limited understanding of host immune response for this fatal disease. To characterize the transcriptional signatures of host inflammatory response to SARS-CoV-2 (HCoV-19) infection, we carried out transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells (PBMC) specimens of COVID-19 patients. Our results reveal distinct host inflammatory cytokine profiles to SARS-CoV-2 infection in patients, and highlight the association between COVID-19 pathogenesis and excessive cytokine release such as CCL2/MCP-1, CXCL10/IP-10, CCL3/MIP-1A, and CCL4/MIP1B. Furthermore, SARS-CoV-2 induced activation of apoptosis and P53 signalling pathway in lymphocytes may be the cause of patients' lymphopenia. The transcriptome dataset of COVID-19 patients would be a valuable resource for clinical guidance on anti-inflammatory medication and understanding the molecular mechansims of host response."],"journal":"Emerg Microbes Infect","authors":["Xiong, Yong","Liu, Yuan","Cao, Liu","Wang, Dehe","Guo, Ming","Jiang, Ao","Guo, Dong","Hu, Wenjia","Yang, Jiayi","Tang, Zhidong","Wu, Honglong","Lin, Yongquan","Zhang, Meiyuan","Zhang, Qi","Shi, Mang","Liu, Yingle","Zhou, Yu","Lan, Ke","Chen, Yu"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32228226","week":"202014|Mar 30 - Apr 05","doi":"10.1080/22221751.2020.1747363","keywords":["COVID-19","cytokine","inflammation","lymphopenia","transcriptome profiling"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135364902913,"score":92.95425},{"pmid":32171193,"title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.","text":["Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.","Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1beta which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1beta which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ralpha receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1beta, IL-6, TNF and CCL2. The suppression of IL-1beta by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1beta and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.","J Biol Regul Homeost Agents","Conti, P","Ronconi, G","Caraffa, A","Gallenga, C","Ross, R","Frydas, I","Kritas, S","32171193"],"abstract":["Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1beta which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1beta which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ralpha receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1beta, IL-6, TNF and CCL2. The suppression of IL-1beta by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1beta and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy."],"journal":"J Biol Regul Homeost Agents","authors":["Conti, P","Ronconi, G","Caraffa, A","Gallenga, C","Ross, R","Frydas, I","Kritas, S"],"date":"2020-03-16T11:00:00Z","year":2020,"_id":"32171193","week":"202012|Mar 16 - Mar 22","doi":"10.23812/CONTI-E","keywords":["*COVID-19","*IL-1","*IL-6","*pro-inflammatory cytokines","*COVI-19","*SARS-CoV-2"],"source":"PubMed","locations":["swabs"],"topics":["Treatment"],"weight":1,"_version_":1663352133952471041,"score":90.16346}]}